14-day Premium Trial Subscription Sign Up For FreeGet Free

Aimmune Therapeutics Stock Forecast NASDAQ:AIMT

$34.49 (0%)

Volume: 0

Closed: Jan 24, 2022

Hollow Logo Score: 0.000

Aimmune Therapeutics Stock Forecast

$34.49 (0%)

Volume: 0

Closed: Jan 24, 2022

Score Hollow Logo 0.000

Aimmune Therapeutics Company Profile

8000 Marina Boulevard

Brisbane CA 94005



Aimmune Therapeutics


Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. Its Characterized Oral Desensitization Immunotherapy includes AR101, a product in Phase 3 registration trial for the treatment of peanut allergy in children and adults. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE